EBITDA Margin % is calculated as EBITDA divided by its Revenue. IDEAYA Biosciences's EBITDA for the
three
months ended in Mar. 2026 was $-107.4 Mil. IDEAYA Biosciences's Revenue for the
three
months ended in Mar. 2026 was $6.6 Mil. Therefore, IDEAYA Biosciences's EBITDA margin for the quarter that ended in Mar. 2026 was -1,637.21%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
IDEAYA Biosciences EBITDA Margin % Related Terms
IDEAYA Biosciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for IDEAYA Biosciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDYA vs MLYS, TARS, DFTX: EBITDA Margin % Comparison
For the Biotechnology subindustry, IDEAYA Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEAYA Biosciences EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where IDEAYA Biosciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEAYA Biosciences (IDYA) has a EBITDA Margin % of -1,637.21% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on IDEAYA Biosciences and its competitors. According to the industry distribution chart, IDEAYA Biosciences ranks #483 out of 945 companies in the Biotechnology industry, placing it in the top 51.1%.
Is IDEAYA Biosciences' EBITDA Margin % too high?
IDEAYA Biosciences' current EBITDA Margin % is -1,637.21%. Based on the distribution chart, IDEAYA Biosciences ranks #483 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, IDEAYA Biosciences has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IDEAYA Biosciences' EBITDA Margin % compare to MLYS and TARS?
According to the Biotechnology industry distribution chart, IDEAYA Biosciences ranks #483 out of 945 companies for EBITDA Margin %. This places IDEAYA Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on IDEAYA Biosciences and its competitors. IDEAYA Biosciences's current EBITDA Margin % is -1,637.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEAYA Biosciences stock overvalued right now?
Based on GuruFocus' analysis, IDEAYA Biosciences (IDYA) is currently considered Possible Value Trap. The stock's GF Value™ is $214.33, compared to a current price of $36.64 — trading 82.9% below its estimated fair value. The current EBITDA Margin % is -1,637.21%. IDEAYA Biosciences' overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For IDEAYA Biosciences (IDYA), the current EBITDA Margin % is -1,637.21% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEAYA Biosciences (IDYA) Overvalued in 2026?
Based on GuruFocus' analysis, IDEAYA Biosciences stock appears to be undervalued.
The current stock price of $36.64 is trading 82.9% below its estimated GF Value™ of $214.33.
GuruFocus considers IDEAYA Biosciences to be Possible Value Trap.
Key valuation signals for IDYA:
EBITDA Margin %: -1,637.21%
GF Value™: $214.33 vs. price of $36.64 (82.9% below fair value)
No single metric tells the full story. See the IDYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
55GF Score
Get the complete analysis for IDYA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDYA has been successfully added to your 
